South Korea · Delayed Price · Currency is KRW Korean Drug Statistics
Total Valuation
Korean Drug has a market cap or net worth of KRW 35.74 billion. The enterprise value is -578.07 million.
| Market Cap | 35.74B |
| Enterprise Value | -578.07M |
Important Dates
The next estimated earnings date is Friday, November 27, 2026.
| Earnings Date | Nov 27, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Korean Drug has 10.91 million shares outstanding. The number of shares has increased by 0.14% in one year.
| Current Share Class | 10.91M |
| Shares Outstanding | 10.91M |
| Shares Change (YoY) | +0.14% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 50.60% |
| Owned by Institutions (%) | n/a |
| Float | 5.39M |
Valuation Ratios
The trailing PE ratio is 23.92.
| PE Ratio | 23.92 |
| Forward PE | n/a |
| PS Ratio | 0.55 |
| PB Ratio | 0.45 |
| P/TBV Ratio | 0.45 |
| P/FCF Ratio | 2.76 |
| P/OCF Ratio | 2.70 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.39, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.39 |
| Quick Ratio | 3.40 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | 0.01 |
| Interest Coverage | 1,813.43 |
Financial Efficiency
Return on equity (ROE) is 1.88% and return on invested capital (ROIC) is 2.89%.
| Return on Equity (ROE) | 1.88% |
| Return on Assets (ROA) | 5.09% |
| Return on Invested Capital (ROIC) | 2.89% |
| Return on Capital Employed (ROCE) | 9.42% |
| Weighted Average Cost of Capital (WACC) | 5.50% |
| Revenue Per Employee | 242.18M |
| Profits Per Employee | 5.49M |
| Employee Count | 270 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 2.02 |
Taxes
In the past 12 months, Korean Drug has paid 7.27 billion in taxes.
| Income Tax | 7.27B |
| Effective Tax Rate | 83.07% |
Stock Price Statistics
The stock price has decreased by -26.07% in the last 52 weeks. The beta is 0.23, so Korean Drug's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | -26.07% |
| 50-Day Moving Average | 3,397.60 |
| 200-Day Moving Average | 3,771.55 |
| Relative Strength Index (RSI) | 41.14 |
| Average Volume (20 Days) | 4,520 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Korean Drug had revenue of KRW 65.39 billion and earned 1.48 billion in profits. Earnings per share was 136.90.
| Revenue | 65.39B |
| Gross Profit | 28.80B |
| Operating Income | 7.70B |
| Pretax Income | 8.75B |
| Net Income | 1.48B |
| EBITDA | 9.68B |
| EBIT | 7.70B |
| Earnings Per Share (EPS) | 136.90 |
Balance Sheet
The company has 36.40 billion in cash and 81.67 million in debt, with a net cash position of 36.31 billion or 3,327.98 per share.
| Cash & Cash Equivalents | 36.40B |
| Total Debt | 81.67M |
| Net Cash | 36.31B |
| Net Cash Per Share | 3,327.98 |
| Equity (Book Value) | 78.82B |
| Book Value Per Share | 7,280.24 |
| Working Capital | 58.16B |
Cash Flow
In the last 12 months, operating cash flow was 13.21 billion and capital expenditures -251.55 million, giving a free cash flow of 12.96 billion.
| Operating Cash Flow | 13.21B |
| Capital Expenditures | -251.55M |
| Depreciation & Amortization | 1.98B |
| Net Borrowing | -82.95M |
| Free Cash Flow | 12.96B |
| FCF Per Share | 1,187.68 |
Margins
Gross margin is 44.05%, with operating and profit margins of 11.78% and 2.27%.
| Gross Margin | 44.05% |
| Operating Margin | 11.78% |
| Pretax Margin | 13.38% |
| Profit Margin | 2.27% |
| EBITDA Margin | 14.81% |
| EBIT Margin | 11.78% |
| FCF Margin | 19.82% |
Dividends & Yields
This stock pays an annual dividend of 160.00, which amounts to a dividend yield of 4.89%.
| Dividend Per Share | 160.00 |
| Dividend Yield | 4.89% |
| Dividend Growth (YoY) | 12.50% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 131.45% |
| FCF Payout Ratio | 15.16% |
| Buyback Yield | -0.14% |
| Shareholder Yield | 4.75% |
| Earnings Yield | 4.15% |
| FCF Yield | 36.27% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Korean Drug has an Altman Z-Score of 4 and a Piotroski F-Score of 5.
| Altman Z-Score | 4 |
| Piotroski F-Score | 5 |